JAZZ PHARMACEUTICALS PLC

Jazz Pharma insider trades signal cautious optimism: CEO/CFO buying, senior exec selling—yet oncology drug JAZ‑001 shows strong Phase II results and a manageable safety profile, positioning the company for near‑term growth.

Jazz Pharma insider sales show disciplined, rule‑based profit‑locking as the CEO’s plan boosts liquidity—yet the bullish outlook and record Q2 growth keep the stock poised for upside.

Jazz Pharmaceuticals insider sale by Smith Mark Douglas shows routine, plan‑based trading—no immediate impact on stock, yet company’s high‑growth pipeline remains bullish.

Jazz Pharmaceuticals insider trading insights: Neena Patil’s disciplined Rule 10b5‑1 sale shows no shift in strategy while the company’s robust pipeline in narcolepsy, oncology and psychiatry continues to advance with promising efficacy data, positi…

Jazz Pharmaceuticals insider selling: how Bruce Cozadd’s 6,000‑share trades signal future risks and potential upside from its oncology pipeline.

Jazz Pharmaceuticals’ insider sale by Bruce Cozadd shows a routine, compliant move amid solid earnings, a diverse pipeline, and strategic growth opportunities.